Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 20/20 | 0.76 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.59 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.59 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5892148 | 0.86 | PLA2G1B (1.00) | PLA2G1BPLA2G2APLA2G5PLA2G2E | |
| SCHEMBL8025842 | 0.84 | PLA2G1B (0.64) | PLA2G1BPLA2G2APLA2G5PLA2G2E | |
| SCHEMBL7011875 | 0.81 | PLA2G1B (1.00) | PLA2G1BPLA2G2APLA2G5PLA2G2E | |
| SCHEMBL7013861 | 0.81 | PLA2G1B (1.00) | PLA2G1BPLA2G2APLA2G5PLA2G2E | |
| SCHEMBL8352190 | 0.78 | PLA2G1B (0.61) | PLA2G1BPLA2G2APLA2G5PLA2G2E | |
| SCHEMBL7006294 | 0.78 | PLA2G1B (0.83) | PLA2G1BPLA2G2APLA2G5PLA2G2E | |
| SCHEMBL7017189 | 0.77 | PLA2G1B (0.84) | PLA2G1BPLA2G2APLA2G5PLA2G2E | |
| SCHEMBL7009615 | 0.77 | PLA2G1B (1.00) | PLA2G1BPLA2G2APLA2G5PLA2G2E | |
| SCHEMBL8026001 | 0.76 | PLA2G1B (0.54) | PLA2G1BPLA2G2APLA2G5PLA2G2E | |
| SCHEMBL7012009 | 0.76 | PLA2G1B (0.80) | PLA2G1BPLA2G2APLA2G5PLA2G2E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043057-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015771-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | PLA2G1B 2638/4885PLA2G2A 2271/4885PLA2G5 2244/4885 |
| US-20070043057-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | PLA2G1B 2638/4885PLA2G2A 2271/4885PLA2G5 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.